AERG


Janney Capital Maintains Buy On Aegerion Ahead Of 2Q14 Earnings Report

In a research report released today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Aegerion Pharmaceuticals¬†(AEGR) with a $90 price target,¬†which …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts